Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 18/20 | 0.57 |
| ▸ | F13A1 | P00488 | 15/20 | 0.53 |
| ▸ | TGM1 | P22735 | 15/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TGM6 | O95932 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14054344 | 0.88 | TGM2 (0.56) | TGM2F13A1TGM1L3MBTL1TGM6 | |
| SCHEMBL14056641 | 0.86 | TGM2 (0.53) | TGM2F13A1TGM1L3MBTL1TGM6 | |
| SCHEMBL14054380 | 0.83 | TGM2 (0.54) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL14057476 | 0.83 | TGM2 (0.52) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL14056432 | 0.82 | TGM2 (0.47) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL14056824 | 0.82 | TGM2 (0.51) | TGM2F13A1TGM1ALDH1A1TGM6 | |
| SCHEMBL14056716 | 0.82 | TGM2 (0.60) | TGM2F13A1TGM1ALDH1A1L3MBTL1 | |
| SCHEMBL14058426 | 0.82 | TGM2 (0.46) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL14057050 | 0.81 | F13A1 (0.48) | TGM2F13A1TGM1ALDH1A1 | |
| SCHEMBL14057122 | 0.81 | TGM2 (0.55) | TGM2F13A1TGM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | TGM2 2/4885F13A1 1540/4885TGM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.